Aceragen (Aceragen) Quality Rank

View and export this data going back to 1996. Start your Free Trial

What is Aceragen Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Aceragen Quality Rank Related Terms

Thank you for viewing the detailed overview of Aceragen's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Aceragen (Aceragen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (NAS:ACGN) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341

Website

https://www.aceragen.com

Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Executives

Vincent Milano	director, officer: President & CEO	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Maxine Gowen	director
Pillar Invest Corp	director, 10 percent owner	C/O PILLAR INVEST OFFSHORE SAL, STARCO CENTER, BLOC B FL3, OMAR DAOUK ST, BEIRUT M8 2020-3313
Atul Chopra	10 percent owner	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
John Clayton Taylor	director, officer: Chief Executive Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Carl N Kraus	officer: Chief Medical Officer	C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Andrew R Jordan	officer: Chief Strategy Officer	C/O GUILFORD PHARMACEUTICALS INC, 6611 TIBUTARY ST., BALTIMORE MD 21224
Daniel Salain	officer: Chief Operating Officer	C/O GRAYBUG VISION, INC., 275 SHORELINE DRIVE, SUITE 450, REDWOOD CITY CA 94065
Ronald J Wooten	director
Nq Pof V Gp, Ltd.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
Novaquest Co-investment Fund Xv, L.p.	director, other: See Remarks	4208 SIX FORKS ROAD, SUITE 920, RALEIGH NC 27609
John J. Kirby	officer: V.P. of Finance, PFO & PAO	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Elizabeth Ann Tarka	officer: Chief Medical Officer	111 WAVERLY CIRCLE, PHOENIXVILLE PA 19460
Bryant David Lim	officer: SVP & General Counsel	C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212, EXTON PA 19341